Zoetis Inc. Class A Common Stock (ZTS): M&A News

ZTS – Abaxis to be acquired by Zoetis for $83 per share in cash, or approximately $2.0 billion.


Key Facts Surrounding This News Item


  • ZTS had a POWR Rating of A (Strong Buy) coming into today.
  • ZTS was 0.84% above its 10-Day Moving Average coming into today.
  • ZTS was -0.62% below its 20-Day Moving Average coming into today.
  • ZTS was -0.26% below its 50-Day Moving Average coming into today.
  • ZTS was 4.19% above its 100-Day Moving Average coming into today.
  • ZTS was 14.36% above its 200-Day Moving Average coming into today.
  • ZTS had returned +15.60% year-to-date leading up to today’s news, versus a +2.00% return from the benchmark S&P 500 during the same period.

More Info About Zoetis Inc. Class A Common Stock (ZTS)


Zoetis Inc. discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. The company was founded in 1952 and is based in Florham Park, New Jersey. View our full ZTS ticker page with ratings, news, and more.

ZTS at a Glance

ZTS Current POWR Rating™
Overall POWR Rating™
ZTS Current Price $84.25 1.45%
More ZTS Ratings, Data, and News

ZTS Price Reaction

The day of this event (May. 16, 2018)
ZTS Closing Price$82.45 0.20%
ZTS Volume3,236,719
29.62% from avg
Leading up to this event
ZTS 1-mo return1.49%
After this event
ZTS 1-day return0.08%
ZTS 3-day return2.76%
ZTS 5-day return2.19%

ZTS Price Chart


The Top Stocks For 2019

More Zoetis Inc. Class A Common Stock (ZTS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ZTS News
Page generated in 0.8365 seconds.